Businesswire News Releases
Feb 04, 2023 12:01 ET
NOTICE: Allianz SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – ALIZY
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Allianz SE (OTC: ALIZY) publicly traded securities between March 9, 2018 and May 17, 2022, inclusive (the “Class Period”) have until April 3, 2023 to seek appointment as lead plainti...
Feb 03, 2023 16:26 ET
CORRECTING and REPLACING Matthew J. Missad named Chairman of the Board for UFP Industries
First paragraph, third sentence of release dated February 3, 2023, should read: "[William G. Currie] then will step down after 54 years with the company."...
Feb 04, 2023 09:09 ET
Dentalis Animal Health appoints Advisory Board
Dentalis Animal Health, a company specializing in Oral Health care for companion animals, has announced the appointment of its Advisory Board....
Feb 03, 2023 22:50 ET
F45 TRAINING 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against F45 Tra
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 6, 2023 to file lead plaintiff applications in a securities class action lawsuit against F45 Training Holdings, Inc. (NYSE: FXLV), if they purchased or acquired the Company’s shares pursuant and/or traceable to the Company’s July 2021 initial public offering (the “IPO”). This action is pending in the United States District Court for the Western District of Texas....
Feb 03, 2023 22:50 ET
INOTIV INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Inotiv, Inc. - NOTV
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Inotiv, Inc. (NasdaqCM: NOTV)....
Feb 03, 2023 22:50 ET
NEOGENOMICS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess Of $100,000 of Deadline in Class Action Lawsuit Against NeoGenom
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 6, 2023 to file lead plaintiff applications in a securities class action lawsuit against NeoGenomics, Inc. (NasdaqCM: NEO), if they purchased the Company’s securities between February 27, 2020 and April 26, 2022, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York....
Feb 03, 2023 22:00 ET
C3 AI Commits to Net-Zero Greenhouse Gas Emissions by 2050
C3 AI (NYSE: AI), the Enterprise AI software application company, today announced its commitment to achieve net-zero greenhouse gas (GHG) emissions by the fiscal year 2050 across scopes 1, 2, and 3 emissions....
Feb 03, 2023 21:00 ET
F45 DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against F45 Training Holdings, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against F45 Training Holdings, Inc. (“F45” or the “Company”) (NYSE: FXLV) in the United States District Court Western District of Texas Austin Division on behalf of all persons and entities who purchased or otherwise acquired F45 securities pursuant to the F45's July 2021 IPO, both dates inclusive (the “Class Period”). Investors have until February 6, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit....
Feb 03, 2023 21:00 ET
NEOGENOMICS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against NeoGenomics, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired NeoGenomics securities between February 27, 2020 and April 26, 2022, both dates inclusive (the “Class Period”). Investors have until February 6, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit....
Feb 03, 2023 21:00 ET
NEWAGE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against NewAge, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against NewAge, Inc. (“NewAge” or the “Company”) (OTC: NBEVQ) in the United States District Court of Colorado on behalf of all persons and entities who purchased or otherwise acquired NewAge securities between January 18, 2018 and October 18, 2022, both dates inclusive (the “Class Period”). Investors have until February 6, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit....
Feb 03, 2023 21:00 ET
SILVERGATE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Silvergate Capital Corporation and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Silvergate Capital Corporation (“Silvergate” or the “Company”) (NYSE: SI) in the United States District Court of Southern California on behalf of all persons and entities who purchased or otherwise acquired Silvergate securities pursuant to the January 20, 2021 SPO; in connection with the December 6, 2021 SPO; and/or from November 9, 2021 to January 5, 2023, both dates inclusive (the “Class Period”). Investors have until February 6, 2023 to appl...
Feb 03, 2023 20:43 ET
American Vanguard Announces Preliminary Unaudited Full Year 2022 Financial Highlights
American Vanguard Corporation (NYSE: AVD), today announced certain key preliminary and unaudited financial results for the full year ended December 31, 2022....
Feb 03, 2023 19:36 ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Atlassian Corporation with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Atlassian Corporation (“Atlassian” or “the Company”) (NASDAQ:
Feb 03, 2023 19:26 ET
Olympia Financial Group Inc. Announces February Dividend
Olympia Financial Group Inc. (TSX: OLY) announces that its Board of Directors has declared a monthly cash dividend on its common shares of $0.35 per common share. The dividend will be payable on February 28, 2023, to shareholders on record as at February 16, 2023. The ex-dividend date is February 15, 2023....
Feb 03, 2023 19:20 ET
Rave Supports Unified ID 2.0 in New Partnership with The Trade Desk
Rave, a global leader in group digital video watching, has announced its support of Unified ID 2.0 (UID2) to hash and salt their audience data for activation by advertisers. Rave’s group video-viewing platform embraces the evolving streaming content landscape, enabling consumers to watch content they love with the people they love, regardless of location. With over 70 million subscribers around the globe, Rave creates a one-of-a-kind, premium streaming experience for consumers....
Feb 03, 2023 18:48 ET
U.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded use of TAKHZYRO® (lanadelumab-flyo) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in pediatric patients 2 to ...
Feb 03, 2023 18:06 ET
KBRA Assigns Preliminary Ratings to LAD Auto Receivables Trust 2023-1
KBRA assigns preliminary ratings to six classes of notes issued by LAD Auto Receivables Trust 2023-1 (“LADAR 2023-1”), an auto loan ABS transaction....
Feb 03, 2023 17:20 ET
Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0676 in B-cell Malignancies
Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug application (IND) for AC0676 for the treatment of patients with relapsed/refractory B-cell malignancies....
Feb 03, 2023 17:16 ET
Sarissa Capital Highlights Amarin’s Disregard for Shareholder Interests and Urges Shareholders to Vote the BLUE Proxy Card for Change at Amarin
Sarissa Capital Management LP (“Sarissa”) today made the following statement on Amarin Corporation plc (NASDAQ: AMRN):...
Feb 03, 2023 08:00 ET
CORRECTING and REPLACING Scotch & Soda Taps Flaunt to Co-Create Web3 Loyalty Program
Please replace the release with the following corrected version due to multiple revisions....
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2023 INK Research Corp. All rights reserved.
US Quotes Data provided by IEX. US Quotes Data provided by IEX. Company fundamental sourced from © Refinitiv. Click for restrictions. © Refinitiv. All rights reserved. Republication or redistribution of Refinitiv, including by framing or similar means, is prohibited without the prior written consent of Refinitiv. Refinitiv is not liable for any errors or delays in Refinitiv content, or for any actions taken in reliance on such content.
US Quotes Data provided by IEX. US Quotes Data provided by IEX. Company fundamental sourced from © Refinitiv. Click for restrictions. © Refinitiv. All rights reserved. Republication or redistribution of Refinitiv, including by framing or similar means, is prohibited without the prior written consent of Refinitiv. Refinitiv is not liable for any errors or delays in Refinitiv content, or for any actions taken in reliance on such content.